 July 26, 2007
|
Norvir/Invirase Go Head-to-Head with Kaletra
Early results from a 48-week clinical trial comparing Norvir (ritonavir)-boosted Invirase (saquinavir) to Kaletra (lopinavir plus ritonavir) suggest that both options are working similarly well in patients starting therapy for the first time, although the rate of virologic failure has thus far been higher in the Norvir/Invirase group.
|
|
|
Starting or Switching: Truvada Outpaces Combivir in Studies
Researchers have reported extended follow-up data from a clinical trial comparing two pairs of nucleoside reverse transcriptase inhibitors (NRTIs), both combined with Sustiva (efavirenz): once-daily Truvada (tenofovir plus lamivudine) plus Emtriva (emtricitabine) versus Combivir (zidovudine plus lamivudine).
|
|
|
Is HIV Treatment Actually Reducing Heart Attack Risk?
New study data reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention indicates that HIV treatment—despite its often negative effects on blood lipid levels—may actually reverse artery hardening that can lead to a heart attack or stroke.
|
|
|
July 25, 2007
|
Sustiva Edges Out Celsentri in Treatment Newbies
A clinical trial has found that Pfizer's CCR5-blocking entry inhibitor, Celsentri (maraviroc), when used by patients starting HIV treatment for the first time, appears somewhat inferior to standard-of-care Sustiva (efavirenz).
|
|
|
Simple Test Can Help Prevent Abacavir Allergy
A clinical trial has confirmed that a simple lab test for a human gene can help prevent a serious allergic reaction caused by abacavir, the active ingredient in Ziagen and a component of Epzicom (Kivexa) and Trizivir.
|
|
|
High Risk of Kidney Problems in HIV
There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney.
|
|
|
Simple Test Eliminates Abacavir Risk
 Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
|
|
|
July 24, 2007
|
Vicriviroc Shows Benefits, Continues Development
The AIDS Clinical Trials Group has reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in the Phase II stage of development.
|
|
|
A Positive Papua New Guinean Speaks Out Against Stigma
 Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
|
|
|
Which HIV Meds Cause Lipoatrophy?
 In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
|
|
|
July 23, 2007
|
Timed Intercourse Plus PrEP for Low-Risk Natural Conception
HIV-negative women who use pre-exposure prophylaxis (PrEP) immediately prior to engaging in carefully timed sexual intercourse with their antiretroviral-treated HIV-positive male partners may further reduce their already low risk of being exposed to the virus.
|
|
|
July 22, 2007
|
Celsentri (Maraviroc) Interaction Warning
Based on a recent drug interaction study, Pfizer is warning that the dose of Celsentri (maraviroc) needs to be altered if the drug is combined with Tibotec’s etravirine and/or Prezista.
|
|
|
AIDS Down Under: IAS Conference Begins in Sydney
The IAS Conference on HIV Pathogenesis, Treatment
and Prevention began with calls
for even greater vigilance to ensure universal access to HIV prevention
and treatment, along with an expansion of research to inform and
strengthen the global response to HIV.
|
|
|
Fauci Defends Bush's AIDS Legacy
 Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
|
|
|
July 20, 2007
|
No Lipodystrophy Approval for Serostim
The Food and Drug Administration (FDA) declined this week to approve EMD Serono’s Serostim for the treatment of HIV-associated adipose redistribution syndrome (HARS)—the accumulation of fat associated with lipodystrophy. As a result, patient access to the drug for HARS will likely be difficult to secure.
|
|
|
July 19, 2007
|
Tenofovir's Long-Term Safety Profile
A certain degree of renal toxicity is apparent in a few HIV patients
receiving therapy with tenofovir disoproxil fumarate, but overall the
drug appears to be safe, according to a new study.
|
|
|
July 16, 2007
|
Despite Flu Shot, Flu Often Occurs in HIV
Fever and respiratory tract symptoms, very common clinical problems in HIV patients, are frequently caused by influenza virus infection, Canadian researchers report in the July 15th issue of Clinical Infectious Diseases.
|
|
|
July 13, 2007
|
Zetia Helps Lower Lipid Lipids in HIV
When added to maximally tolerated lipid lowering therapy in patients with HIV dyslipidemia, ezetimibe helps further lower lipids, according to a new study.
|
|
|
July 12, 2007
|
New Method Identifies Rare Resistance Mutations
A new method that combines DNA bar coding and pyrosequencing can identify multiple rare HIV drug resistance mutations in a single test, according to a report in the June 18th Nucleic Acids Research.
|
|
|
July 11, 2007
|
HIV Treatment Boosts Birth Rate
Compared with the live birth rate in HIV-infected women before the advent of highly active antiretroviral therapy (HAART), the rate in the HAART era has increased 150%, investigators with the Women's Interagency HIV Study report in the June issue of the American Journal of Obstetrics and Gynecology.
|
|
|
July 09, 2007
|
HIV Increases Lung Cancer Risk
Independent of smoking, HIV infection is associated with an elevated
risk for developing lung cancer, according to a report in the July 1st
Clinical Infectious Diseases.
|
|
|
July 06, 2007
|
Dynamic Duo Etravirine and Prezista Shine in Studies
Data from two ongoing Phase III studies indicate that Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (TMC-125), combined with their approved protease inhibitor (PI) Prezista (darunavir), packs a powerful antiviral punch in HIV-positive patients with documented NNRTI and PI resistance.
|
|
|
July 05, 2007
|
Children's Sustiva Dose May Need to be Upped
In developing countries where therapeutic drug level monitoring is not readily available, HIV-infected children taking efavirenz are likely to be undertreated, according to a research team in South Africa.
|
|
|
July 02, 2007
|
HIV Treatment Increases Risk of Diabetes
Patients with HIV infection on most highly active antiretroviral therapy (HAART) regimens have an increased incidence of new-onset type 2 diabetes mellitus, the latest findings of the Swiss HIV Cohort Study show.
|
|
|
|
Regan Hofmann talks with Dr. Nancy Padian about PrEP, microbicides, and circumcision, and asks "when can my boyfriend and I stop using condoms." 
Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors. 
In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV. 
A videocast interview with Professor Brian Gazzard, an expert on HIV and aging.
